FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406.

Published: 22nd March 2019

Authors: Conroy T, Hammel P, Hebbar M, Abdelghani MB, Wei AC, Raoul J-L et al.

Conclusion

Some 593 patients were followed for a median of 33.6 months. Disease-free survival was improved with FOLFIRINOX (21.6 months) compared to gemcitabine (12.8 months; P=0<0.001).Overall 3-year survival rates were 63.4 and 48.6 per cent, respectively.

Pubmed Link

Your comments

0 Comments